"A $7.25 billion settlement aims to resolve nearly all current and future U.S. claims linking Roundup weedkiller to non-Hodgkin lymphoma, impacting millions exposed to the product, even those not yet diagnosed with cancer."
A pivotal hearing is set to take place in St. Louis on Monday, September 14, where a Missouri judge will begin evaluating the final approval of a substantial $7.25 billion settlement. This agreement is designed to address the vast majority of current and future lawsuits alleging that the widely used Roundup weedkiller, manufactured by Bayer (formerly Monsanto), has caused non-Hodgkin lymphoma. While Judge Timothy Boyer of the Circuit Court of the City of St. Louis is not expected to render an immediate decision at this hearing, the proceedings represent a critical juncture in one of the most significant legal battles surrounding agricultural chemicals in recent history. The hearing itself marks a shift from its originally scheduled date of August 19, underscoring the complex legal preparations involved.
The implications of this proposed settlement extend far beyond the individuals who have already filed claims. According to the court-authorized settlement website, the agreement is poised to cover a broad spectrum of individuals who have been exposed to Roundup products within the United States prior to February 17, 2026. Crucially, the settlement explicitly warns that it "will affect you even if you have not been diagnosed with cancer," highlighting the proactive nature of the agreement and its intention to encompass potential future cases. This broad scope transforms a courtroom dispute into a matter of significant personal consideration for a vast array of people, including farmers, landscapers, groundskeepers, and countless homeowners who have relied on Roundup for weed control over many years. Should the court grant final approval, class members who subsequently develop non-Hodgkin lymphoma will generally be directed to pursue compensation through a claims program rather than initiating individual lawsuits. The window for eligible individuals to opt out of the settlement, thereby preserving their right to pursue independent legal action, closed on June 4.
Payment Tiers and Eligibility Criteria Detailed
Bayer is currently facing an estimated 65,000 claims across state and federal courts, as reported by Reuters. The proposed $7.25 billion settlement is a comprehensive effort to resolve nearly all of these existing and potential future claims originating in the United States. The official settlement website outlines a tiered system for potential awards, with amounts ranging from a minimum of $6,000 to over $165,000. Reuters has provided further detail, specifying payouts for individuals diagnosed with non-Hodgkin lymphoma between $10,000 and $165,000. The final compensation amount for each claimant will be determined by a complex set of factors, including the severity of their diagnosed disease, their age at the time of diagnosis, and the nature of their exposure, differentiating between occupational and residential use. Under the terms of the proposed agreement, Monsanto would commit to making declining, capped annual payments over a period of up to 21 years. A critical condition of the settlement is Bayer’s right to terminate the agreement if an unmanageable number of individuals choose to opt out.
Individuals who have already received a diagnosis of non-Hodgkin lymphoma and are eligible for compensation will have a 180-day period following the court’s final approval to register their claim. For those who have been exposed but have not yet developed the condition, no immediate registration is required. They will have the opportunity to file a claim within six years of their diagnosis or before the program’s 16th annual payment date, whichever comes first.
The initial proposal for this class settlement was formally announced by Monsanto on February 17, with the court granting preliminary approval on March 4. This current agreement follows a previous settlement in 2020, valued at approximately $10 billion, which successfully resolved many existing lawsuits but left Bayer vulnerable to future claims. This new, broader settlement aims to provide a more definitive resolution.
Advocates for the settlement argue that it provides a guaranteed pathway to compensation at a time when the legal landscape has become increasingly challenging for plaintiffs. A significant development occurred on June 25 when the U.S. Supreme Court, in a 7-2 decision, ruled that federal pesticide law preempts state lawsuits alleging that Monsanto failed to adequately warn consumers about the potential cancer risks associated with Roundup’s labels. This ruling, as reported by CBS News, significantly curtailed the ability of plaintiffs to pursue claims based on inadequate labeling in state courts.
Christopher Seeger, an attorney who would represent current claimants, stated at the time of the settlement’s announcement that its design was intended to ensure that both present and future patients "have access to meaningful compensation," according to the Associated Press.
However, the settlement has also faced considerable criticism. Attorney Matt Clement, representing approximately 280 plaintiffs, expressed to the AP that the proposed payouts are "exceedingly too small." Opponents of the deal also contend that it unfairly binds future claimants who might prefer to litigate their cases independently. A spokesperson for Monsanto, in response to Reuters, conveyed the company’s belief that the settlement "is fair to all parties and warrants final approval."
A Legal Accord, Not a Scientific Determination
It is imperative to understand that this settlement, if approved, does not constitute a scientific verdict on whether Roundup causes cancer. The scientific and regulatory communities have presented differing perspectives on the matter. In 2015, the International Agency for Research on Cancer (IARC), a branch of the World Health Organization, classified glyphosate, the primary active ingredient in Roundup, as "probably carcinogenic to humans." Conversely, the U.S. Environmental Protection Agency (EPA) concluded in 2017 that glyphosate was not likely to cause cancer in humans at expected exposure levels. The EPA is currently undertaking an updated human health risk assessment, with completion anticipated in late 2026. Notably, the EPA does not mandate a cancer warning on Roundup’s product labels.
Research on the topic has yielded mixed results. A substantial study supported by the National Cancer Institute, published in 2018, examined pesticide applicators and found no overall association between glyphosate exposure and non-Hodgkin lymphoma. However, some subsequent pooled analyses of existing research have suggested a potentially higher risk among individuals with the most significant occupational exposure. Bayer consistently denies that glyphosate causes cancer, and the settlement agreement explicitly includes no admission of liability on the part of the company. Therefore, any payment received by an individual through this settlement should not be interpreted as a legal finding that Roundup caused their specific cancer diagnosis. Instead, it reflects a resolution of legal uncertainties and potential liabilities for both parties involved.
In response to the ongoing litigation, Bayer has already ceased the sale of Roundup products containing glyphosate for residential lawns and gardens in the United States, as reported by the AP. However, glyphosate remains a widely utilized herbicide in agricultural settings across the country.
Practical Guidance for Exposed Individuals and Their Families
Non-Hodgkin lymphoma is a type of cancer that originates in the lymphatic system, a critical component of the immune system. Recognizing potential warning signs is crucial for early detection. These symptoms can include painless swelling of lymph nodes, commonly found in the neck, armpit, or groin area. Other indicators may involve unexplained fever, drenching night sweats, unintentional weight loss, and persistent fatigue that does not improve with rest. While these symptoms can be indicative of numerous conditions, individuals experiencing them for more than a few weeks should consult a healthcare professional. In cases of difficulty breathing, severe chest pain, or rapidly worsening symptoms, immediate medical attention is necessary.
Individuals with occupations that involve prolonged and heavy use of herbicides, such as farmworkers, landscapers, and groundskeepers, are considered to have the highest potential for exposure. For anyone who handles weedkillers, minimizing direct contact is paramount. This can be achieved by strictly adhering to product label instructions, consistently wearing protective gear such as gloves and long-sleeved clothing, and thoroughly washing exposed skin and clothing immediately after application.
Individuals who believe they may be eligible class members are encouraged to sign up for updates via the official settlement website. It is important to note that the registration and claims process will only commence if the court grants final approval. The settlement administrator, BrownGreer, will be responsible for managing these processes. For those who may file a claim, maintaining detailed records of their diagnosis dates, documented exposure history to Roundup, and any related medical treatments can significantly streamline the claims process. Individuals newly diagnosed with lymphoma are also advised to discuss the specific subtype of their cancer with their oncologist, as the various forms of non-Hodgkin lymphoma can differ considerably in terms of treatment approaches and prognosis.
It is important for the public to exercise caution regarding any advertising that makes specific promises about settlement payouts. The court-authorized website and its designated administrator are the sole official sources for accurate eligibility information and claim procedures. Furthermore, settlement payments are entirely separate from medical care. Anyone experiencing potential symptoms of non-Hodgkin lymphoma should not delay seeking medical evaluation while awaiting the outcome of the court proceedings.
The ultimate decision on the final approval of this settlement now rests with Judge Boyer. While a ruling is not anticipated on the day of the hearing, any approval could potentially be subject to appeals, which might further delay the disbursement of funds. The proposed deal encompasses a significantly larger group of individuals than those currently involved in active litigation. The scientific debate surrounding the link between Roundup and cancer remains ongoing, and it is crucial for individuals experiencing persistent lymphoma warning signs to seek medical attention irrespective of the court’s decision.
Key Questions Answered
What is happening Monday?
A judge in St. Louis will preside over a fairness hearing to determine whether to grant final approval to Monsanto’s proposed $7.25 billion class settlement concerning Roundup claims. No immediate ruling is expected at this hearing.
Who is covered by the settlement?
The settlement is designed to cover individuals exposed to Roundup products in the United States before February 17, 2026. This includes those who have not yet been diagnosed with non-Hodgkin lymphoma, provided they did not opt out of the settlement.
How much could people receive?
The official settlement website indicates that potential awards could range from $6,000 to over $165,000. The final amount will depend on individual circumstances, such as the severity of the disease, age at diagnosis, and the type of exposure (e.g., occupational vs. residential).
Can I still opt out?
No. The deadline for eligible individuals to opt out of the settlement and retain the right to pursue individual lawsuits was June 4, 2026, according to the official settlement website.
Does the settlement prove Roundup causes cancer?
No. The settlement is a legal agreement to resolve claims and does not represent an admission of liability by Bayer. Bayer continues to deny that glyphosate causes cancer, and scientific agencies have reached differing conclusions on the matter. A payment from the settlement is not a medical finding.
What lymphoma symptoms should people watch for?
Key symptoms to monitor include painless swollen lymph nodes, unexplained fever, drenching night sweats, unintentional weight loss, and persistent fatigue lasting for more than a few weeks. Anyone experiencing these should consult a clinician.
When could payments begin?
Payments cannot commence until after the court grants final approval and any subsequent appeals are resolved. Individuals who have been diagnosed with non-Hodgkin lymphoma would have 180 days from the date of final approval to register their claim.
